The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and development expenditures to the Securities and Exchange Commission.
Latest Action
Referred to the Subcommittee on Health.
AI Summary
Plain-English explanation of this bill
The Pharmaceutical Research Transparency Act would require the disclosure of costs associated with clinical trials and pharmaceutical research and development. It would create a public registry of cost data for certain clinical trials and mandate that drug manufacturers report their research and development expenditures to the Securities and Exchange Commission.
Last updated: 12/29/2025
Official Summary
Congressional Research Service summary
<p><strong>Pharmaceutical Research Transparency Act of 2023</strong></p> <p>This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.</p> <p>Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.</p> <p>The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.</p>
Key Points
Main provisions of the bill
Requires the National Institutes of Health to create a public registry of cost data, including total and per-patient costs, for certain clinical trials testing drugs, biological products, and devices.
Mandates that drug manufacturers include their research and development expenditures in their annual disclosures to the Securities and Exchange Commission.
Aims to increase transparency around the costs of pharmaceutical research and development.
How This Impacts Americans
Potential effects on citizens and communities
If this bill becomes law, it would affect pharmaceutical companies, patients, and the general public. Increased transparency around the costs of drug development could inform policy decisions and help patients understand the pricing of medications. The public registry could also provide valuable information for researchers and healthcare providers.
Policy Areas
Primary Policy Area
Health
Related Subjects
Administrative law and regulatory procedures
Department of Health and Human Services
Government information and archives
Manufacturing
Medical research
Prescription drugs
Research and development
Scope & Jurisdiction
Jurisdiction Level
federal
Congressional Session
119th Congress
Citation Reference
3160, 119th Congress (2025). "PREVAIL Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3160
